PROGRAM OVERVIEW

Let's talk lipids in the Music City! Join the National Lipid Association for the Fall Clinical Lipid Update Sept. 21-23 at the Loews Vanderbilt Hotel in Nashville for another premier event packed with an incredible agenda.

Key topics include: 

  • Emerging Science in Clinical Lipidology
  • Lipoprotein(a): The Neglected CVD Risk Factor
  • Plaque Biology and Implications for Clinical Practice

Earn up to 12.5 hours of CME/CE and hear from renowned faculty while networking with some of the greatest minds in clinical lipidology. Stay at the top of your profession by registering now to attend this important event!

*The room block at the Loews Vanderbilt Hotel is currently SOLD OUT! We recommend that attendees explore other area hotels.*

You may need to disable administrative overlay in your Drupal record

Edit Parent - PROGRAM (visibility Show)

AGENDA


Friday, September 21
3:45-3:55PM Chapter Presidents Welcome & Introduction
Session I: Defining Targets, Goals and Thresholds for Treatment
3:55-4:00PM ARS Questions
4:00-4:25PM Best Target for Treatment: What Do the Clinical Trials Show and Why Did We End Up With LDL-C? Dean G. Karalis, MD, FNLA
4:25-4:50PM LDL-C: Are We Assessing This Right? Seth S. Martin, MD, MHS
4:50-5:15PM LDL-C Lowering and Cardiovascular Risk Reduction in CTT: Is it Absolute, Relative or Both? Karen E. Aspry, MD, MS, FNLA
5:15-5:40PM When to Scratch Below the Surface: Indications for Advanced Lipid Testing Debra A. Friedrich, DNP, FNP-BC, CLS, FNLA
5:40-6:00PM ARS Questions and Q&A Panel
6:00-7:00PM Welcome Reception in Exhibit Hall
7:00-9:00PM CME/CE Dinner Symposium – PCSK9 Inhibitors in Practice: Real-World Challenges and Solutions
9:00-10:00PM NLA New Member Game Night
Saturday, September 22
6:30-8:00AM CME/CE Breakfast Symposium
7:00-7:50AM Breakfast in Exhibit Hall
7:50-8:00AM Housekeeping Notes & ARS Questions for Session II
Session II - Back to Basics: Lifestyle Strategies in the Management of Dyslipidemia
8:00-8:20AM Talking to your Patients About Trending Diets Karen K. Collins, MS, RDN, CDN, FAND
8:20-8:40AM Evidence Based Cardioprotective Dietary Patterns Alice H. Lichtenstein, DSc, MS
8:40-9:00AM Let’s Make a Move: Physical Activity in ASCVD Risk Reduction Debra A. Friedrich, DNP, FNP-BC, CLS, FNLA
9:00-9:20AM ARS Questions and Q&A Panel
9:20-9:50AM Break in Exhibit Hall
9:50-10:15AM Clinical Pearls for the Lipidologist – Sweet and Low (Risk): Managing ASCVD Risk in Diabetes                                             John M. Stafford, MD, PhD
Session III: Emerging Science in Clinical Lipidology
10:15-10:20AM ARS Questions
10:20-10:40AM 2017-2018 Journal of Clinical Lipidology Year in Review: The Intersection of Science and Clinical Practice John R. Guyton, MD, FNLA
10:40-11:00AM PCSK9 Inhibitors in Perspective: How Does the Evidence Impact Clinical Practice? Christopher P. Cannon, MD
11:00-11:20AM PAD: An Indicator of High CVD Risk as Well as Substantial Risk Reduction Potential with Lipid Lowering Therapy  Marc P. Bonaca, MD, MPH
11:20-11:40AM ARS Questions and Q&A Panel
11:40-11:55AM SELA & NELA News & Notes
11:55AM-12:55PM Lunch in Exhibit Hall
12:55-1:20PM Clinical Pearls for the Lipidologist – Handling the Pressure: Measuring Blood Pressure 101 for Clinicians on the Run Jan N. Basile, MD
Session IV: Lipoprotein(a): The Neglected CVD Risk Factor
1:20-1:25PM ARS Questions
1:25-1:35PM Case Presentation Seth S. Martin, MD, MHS
1:35-1:55PM Lp(a) and ASCVD Risk: Indications for Testing and Family Screening Keith C. Ferdinand, MD, FNLA
1:55-2:15PM Aortic Stenosis and Lp(a): Mechanisms and Implications James A. Underberg, MD, MS, FNLA
2:15-2:35PM Residual ASCVD Risk and Lp(a): Therapeutic Considerations in the High-Risk Patient Linda C. Hemphill, MD, FNLA
2:35-2:55PM ARS Questions and Q&A Panel
2:55-3:20PM Clinical Pearls for the Lipidologist – No Drugs for Me: Dietary Supplements in ASCVD Risk Reduction Barbara S. Wiggins, PharmD, CLS, FNLA
3:20-3:35PM Break
NLA Special Session – Bridging the Gaps in Treatment of Genetic Triglyceride Disorders: A Team-Based Approach to Differential Diagnoses and Management
3:35-3:40PM Pre-Activity Self-Assessment of Competencies
3:40-4:10PM Genetic Triglyceride Disorders- Overview, Mechanism of Disease and Clinical and Genetic Presentations Daniel E. Soffer, MD, FNLA
4:10-4:20PM Patient Case Vignette: Guess the Diagnosis

Vikesh K. Singh, MD, MSc

4:20-4:55PM Formulating a Comprehensive Management Plan Vikesh K. Singh, MD, MSc,
Daniel E. Soffer, MD, FNLA,
Kellie H. McLain, ANP-BC, CLS, FNLA
Lori A. Alexander, MSHS, RD, CLS, FNLA,
Joseph J. Saseen, PharmD, CLS, FNLA
4:55-5:05PM Questions & Answers
5:05-5:10PM Post-Activity Self-Assessment of Competencies
6:30PM Foundation of the NLA Event
Sunday, September 23, 2018
7:00-7:50AM Breakfast
7:50-8:00AM Housekeeping Notes & ARS Questions for Session V
Session V: Complex Cases with the "Aces"
8:00-8:07AM Complex Case—Patient with Primary Biliary Cirrhosis, Severe Hypercholesterolemia

Jr. Faculty- Kathleen H. Byrne, CRNP
Expert- John R. Guyton, MD, FNLA

8:07-8:25AM Expert Panel—Differential Diagnoses and Management of Dyslipidemia in Liver Disease Including NASH, Chronic Hepatitis, Primary Biliary Cirrhosis and Lipoprotein-X
8:25-8:32AM Complex Case—Patient with Severe Hypercholesterolemia, Tuboeruptive Xanthomas over Knees and Elbows with Palmar Xanthomas

Jr. Faculty- Anish K. Vani, MD
Expert- Daniel E. Soffer, MD, FNLA

8:32-8:52AM Expert Panel—Differential Diagnoses, Genetics and Management of Familial Dysbetalipoproteinemia
8:52-9:00AM Complex Case—Patient with Statin Intolerance, Drug-Drug Interaction Complications and is Nonadherent

Jr. Faculty- Jan L. McAlister, DNP, CLS, FNLA
Expert- Anne C. Goldberg, MD, FNLA

9:00-9:20AM Expert Panel—Management Options for Statin Intolerance and Ways to Improve Adherence
9:20-9:40AM ARS Questions and Q&A Panel
Session VI: Plaque Biology and Implications for Clinical Practice
9:40-9:45AM ARS Questions
9:45-10:05AM The Pathobiology of Atherosclerosis: Understanding Calcification and Clinical Implications Edward Fisher, MD, PhD, FNLA
10:05-10:25AM Best Practices in Plaque Imaging: A 2018 Update Michael J. Blaha, MD, MPH
10:25-10:45AM Statins and Coronary Artery Calcification: Friend or Foe? Edward Gill, MD, FNLA
10:45-11:05AM ARS Questions and Q&A Panel
11:05AM Adjourn

ANCILLARY COURSES


Are you new to Lipidology or just looking to brush up on the changing information coming out in the field? Attend one of our ancillary courses taught by Experts in the area of Lipidology:

The NLA's Masters in Lipidology course provides an advanced examination of the core curriculum in Clinical Lipidology. This course is designed for any health care professional with experience in Lipidology who desires advanced training. Experts in the field of Lipidology will lecture on advanced concepts and guide participants through interactive learning scenarios that provide tools and skills to further advance personal standards of practice. It is recommended that attendees have already completed preparatory coursework (eg Foundations of Lipidology [formerly Lipid Academy] or similar core curriculum training).

The NLA's Foundations of Lipidology course, formerly Lipid Academy, provides an introductory review of the core curriculum in Clinical Lipidology. This course is designed for any healthcare professional seeking to learn the fundamentals of Lipidology. Experts in Lipidology will lecture on basic concepts and guide participants through interactive learning scenarios that provide the knowledge and tools necessary to work effectively in a lipid practice, and prepare for advanced training.

ACCREDITATION INFORMATION


 

Target Audience
This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, nurse practitioners, advance practice registered nurses and registered dietitians with an interest in lipid management.

Type of Activity
Live Activity
Application

Educational Objectives
At the conclusion of this activity, all participants should be able to:

  • Discuss strategies to improve the knowledge, skills or performance of the healthcare team.

Session I: Defining Targets, Goals, and Thresholds for Treatment

  • Define lipid treatment goals for patients with dyslipidemia.
  • Describe the various measurements of low-density lipoprotein (LDL-C) and the effect on clinical decisions.
  • Review the evidence for benefit from LDL-C lowering therapies.
  • Evaluate clinical scenarios where additional lipid testing may inform clinical decisions.

Session II: Back to Basics: Lifestyle Strategies in the Management of Dyslipidemia

  • Outline the impact of various diets on short and long-term weight loss.
  • Utilize effective diet and lifestyle strategies for dyslipidemia management.
  • Assess the impact of increasing physical activity on Atherosclerotic Cardiovascular Disease (ASCVD) risk.

Clinical Pearls for the Lipidologist

  • Discuss practical strategies for the optimal preventive therapy in diabetes.
  • Discuss practical strategies for evaluating blood pressure in the clinic.
  • Discuss practical non-prescription treatment strategies for ASCVD prevention.

Session III: Emerging Science in Clinical Lipidology

  • Review the practical implications of current publications to the evaluation and management of patients with dyslipidemia.
  • Assess the implications of recent ASCVD outcomes data for the clinical management of patients with dyslipidemia.
  • Evaluate current and novel biomarkers and their impact on Cardiovascular (CV) risk detection and management.

Session IV: Lipoprotein(a): The Neglected CVD Risk Factor

  • Review current recommendations for Lipoprotein(a) (Lp(a)) screening.
  • Determine possible association between Lp(a) levels and the development of aortic stenosis.
  • Define treatment options to reduce residual ASCVD risk.

NLA Special Session: Bridging the Gaps in Treatment of Genetic Triglyceride Disorders: A Team-Based Approach to Differential Diagnoses and Management

  • Identify genetic triglyceride disorders, including Familial Combined Hyperlipidemia, Hypertriglyceridemia and Familial Chylomicronemia Syndrome (FCS), in clinical practice.
  • Review current management recommendations and emerging therapeutic interventions for improving the outcomes in patients with FCS.
  • Implement a team-based approach to the clinical management of FCS, effectively involving lipidologists, gastroenterologists, nurses, pharmacists, dietitians, lifestyle educators and other healthcare professionals.

Session V: Complex Cases with the “Aces”

  • Discuss complex lipid case management for clinical lipidologists.

Session VI: Plaque Biology and Implications for Clinical Practice

  • Review the pathogenesis of atherosclerotic plaque development and progression.
  • Discuss the roles of imaging in cardiovascular disease risk evaluation.
  • Review the atherosclerotic plague effects of various lipid treatment strategies.

Criteria for Success:
Statements of credit will be awarded based on the participant´s attendance and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/claimed credit form at lipid.org/cme.
For Pharmacists: Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within four weeks.

Disclosure Statement:
It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by NLA prior to accreditation of the activity.

Commercial Support:
Full notification of commercial support will be provided in the activity accreditation.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 11.25 AMA PRA Category 1 Credits™ MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

In support of improving patient care, this activity has been planned and implemented by The National Lipid Association. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit Designation Statement
The National Lipid Association designates this live activity for a maximum of 12.50 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Dietitians
The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 12.50 continuing professional education units (CPEUs) for completion of this program/ materials. CDR Accredited Provider #NL002.


Pharmacist Accreditation Statement
Universal Activity Number JA0007192-0000-18-019-L01-P (Application)
This Activity has been approved for 12.50 contact hour(s) (1.250 CEUs) of the Accreditation Council for Pharmacy Education

Nursing
The maximum number of hours awarded for this CE activity is 12.4 contact hours.
Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

Foundations of Lipidology
In support of improving patient care, this activity has been planned and implemented by The National Lipid Association. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit Designation Statement
The National Lipid Association designates this live activity for a maximum of 13.25 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by ACCME.

Dietitians
The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 13 continuing professional education units (CPEUs) for completion of this program/materials. CDR Accredited Provider #NL002.

Pharmacists
Universal Activity Number – JA0007192-0000-18-017-L01-P (Application)
This Activity has been approved for 13.25 contact hour(s) (1.325 CEUs) of the Accreditation Council for Pharmacy Education.

Nursing
The maximum number of hours awarded for this CE activity is 13.3 contact hours.
Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

Masters in Lipidology
In support of improving patient care, this activity has been planned and implemented by The National Lipid Association. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit Designation Statement
The National Lipid Association designates this live activity for a maximum of 14.75 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by ACCME.

Dietitians
The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 14 continuing professional education units (CPEUs) for completion of this program/ materials. CDR Accredited Provider #NL002.

Pharmacists
Universal Activity Number – JA0007192-0000-18-018-L01-P (Application)
This Activity has been approved for 14.75 contact hour(s) (1.475 CEUs) of the Accreditation Council for Pharmacy Education.

Nursing
The maximum number of hours awarded for this CE activity is 14.7 contact hours.
Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

Delete PROGRAM

Edit Parent - ENGAGE (visibility Show)

SOCIAL MEDIA


#NLANashville

Be part of the conversation and get the latest news and announcements from the Fall CLU. Follow the NLA on Facebook, Twitter, LinkedIn and Instagram. Use the hashtag #NLANashville when posting about the meeting.

CONNECT WITH EXHIBITORS


Accreditation Council for Clinical Lipidology
The ACCL offers the Clinical Lipid Specialist (CLS) certification program to licensed physicians, nurses, nurse practitioners, physician assistants, pharmacists, registered dietitian/nutritionists, clinical exercise physiologists and other healthcare professionals who meet qualifying criteria. The CLS program certifies and validates one's professional credentials to provide specialized care to patients with dyslipidemia and related cardiometabolic conditions.
www.lipidspecialist.org

Aegerion Pharmaceuticals
Novelion Therapeutics is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases. Novelion has a diversified commercial portfolio through its indirect subsidiary, Aegerion Pharmaceuticals, Inc., which includes JUXTAPID® and MYALEPT®. The company seeks to advance its portfolio of rare disease therapies by investing in science and clinical development.
www.novelion.com

Akcea Therapeutics
Akcea Therapeutics is a pharmaceutical development and commercialization company focused on helping patients living with serious cardiometabolic lipid disorders.  Akcea’s pipeline includes advanced RNA-targeted antisense therapeutics being investigated to treat patients with a wide range of lipid disorders including rare hyperlipidemias, hyperlipoproteinemia(a), and hypertriglyceridemia with cardiovascular risk. Volanesorsen, Akcea's most advanced investigational drug, has completed Phase 3 trials to reduce ApoC-III protein production and to lower triglycerides to treat patients with familial chylomicronemia syndrome (FCS) and is in Phase 3 trials for patients with familial partial lipodystrophy (FPL). 
www.akceatx.com

Alexion Pharmaceuticals
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases, including lysosomal acid lipase deficiency (LAL-D), through the innovation, development and commercialization of life-changing therapies.
www.alexion.com

Amarin Pharma, Inc.
Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Vascepa® (icosapent ethyl), Amarin's first FDA approved product, is a pure, EPA-only, omega-3 fatty acid product available by prescription. 
www.amarincorp.com

Ambry Genetics
We believe in the power of people working together towards one goal, one purpose. And the power that lies within our walls to make a life-changing difference. We will not stop until human disease is understood.
www.ambrygen.com

American Board of Clinical Lipidology
The ABCL is an independent physician-certifying organization offering the highest benchmark of professional competency in Clinical Lipidology. Enhance your professional stature and credibility in the field, and demonstrate your commitment to the highest standards of patient care. The program is open to licensed physicians in the US and Canada.
www.lipidboard.org

Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
www.amgen.com

Boston Heart Diagnostics
Boston Heart Diagnostics recognizes that CVD and diabetes are complex and every patient’s story is different. A patient’s treatment plan needs to be individualized if we are to make a significant impact to improve health outcomes. Boston Heart is transforming the standard of care by providing tailored patient reports, which are created by integrating a patient’s test results, health history and food likes and dislikes. This comprehensive approach offers a more complete picture of a patient’s health. Boston Heart’s patient and healthcare provider portals are used to deliver these reports in a secure, protected environment. Boston Heart’s solutions are designed to engage and educate patients on the actions they can take toward achieving and maintaining a healthier lifestyle.
www.bostonheartdiagnostics.com

Kaneka Pharma America

Kowa Pharmaceuticals
Established in 2008, Kowa Pharmaceuticals America, Inc., is committed to developing and delivering safe, effective solutions in the field of cardiometabolic therapeutics. We do this by maintaining high ethical and professional standards--and it all starts with people. By empowering our employees to live this mission, we can create a healthier vision for the future.
www.kowapharma.com

Medicure Pharma, Inc.
Medicure Pharma is focused on the development and commercialization of a growing portfolio of cardiovascular therapeutics for the U.S. market. We have an unwavering focus on delivering safe, efficacious and cost-effective medicines that benefit patients and healthcare providers.
www.medicure.com

Phosphorus Diagnostics
Phosphorus is a computational genomics company with the vision to create a world where every healthcare decision is optimized with genomics. Phosphorus offers clinical genetic tests in a range of clinical areas from its CLIA-certified laboratory. We also develop powerful software that enables labs around the world to deliver the most advanced genetic tests.
www.phosphorus.com

Quest Diagnostics
Quest Diagnostics, the world’s leading provider of diagnostic testing, information and services, offers the Cardio IQ Solution—a comprehensive approach to heart health.
www.questdiagnostics.com

Retrophin Inc.
Retrophin is a biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options.
www.retrophin.com

Sanofi-Regeneron
Sanofi, a global healthcare leader, discovers, develops, and distributes therapeutic solutions focused on patients’ needs. Regeneron, a leading biopharmaceutical company, discovers, develops, manufactures, and commercializes biologic medicines for serious medical conditions. Since 2007, Sanofi and Regeneron have collaborated to develop and commercialize fully human monoclonal antibodies utilizing proprietary technologies.
www.sanofi.us/en/

VAP Diagnostics
VAP Diagnostics Lab is a clinical reference laboratory specializing in cardiometabolic testing and disease management. VAP Diagnostics provides clinicians with a single source for the proprietary VAP+® Test and other standard and specialty cardiometabolic tests, as well as customizable disease state panels. Using direct (not estimated) measurement, VAP+ identifies cholesterol, triglyceride and genetic lipid disorders, enabling health care professionals to accurately stratify cardiovascular risk and recommend personalized treatment strategies to improve health outcomes. Vertical Auto Profile (VAP+) technology reveals residual cardiometabolic risk as recommended in the NCEP ATP III, ADA/ACC Joint Consensus and AACE guidelines
www.vapdiagnostics.com 

Delete ENGAGE

Edit Parent - VENUE (visibility Show)

VENUE INFORMATION


Loews Vanderbilt Hotel

2100 West End Avenue
Nashville, TN
Meeting Room Rate: $225/night plus tax
ROOM BLOCK CURRENTLY SOLD OUT!
Please see below for other area hotels.

More about the venue

OTHER AREA HOTELS


Aloft Nashville West End

1719 West End Avenue
Nashville, TN
Just a 0.5 mile walk to the Loews Vanderbilt Hotel
Visit 
aloftnashvillewestend.com to book your room.

 

 

Springhill Suites Vanderbilt/West End

1800 West End Avenue
Nashville, TN
Just a 0.4 mile walk to the Loews Vanderbilt Hotel
Visit 
marriott.com to book your room.

 

 

Hilton Garden Inn Nashville Vanderbilt

1715 Broadway
Nashville, TN
Just a 0.5 mile walk to the Loews Vanderbilt Hotel
Visit 
hiltongardeninn3.hilton.com to book your room.

 

 

Kimpton Aertson Hotel

2021 Broadway
Nashville, TN
Just a 0.3 mile walk to the Loews Vanderbilt Hotel
Visit 
aertsonhotel.com to book your room.

 

 

VISIT NASHVILLE


Grand Ole Opry

Nothing says “Nashville" like a night at the Grand Ole Opry. What began as a simple radio broadcast in 1925 is today an entertainment phenomenon showcasing a mix of country music greats-- new stars, superstars, and legends. Among the Opry's current members are Dierks Bentley, Charlie Daniels, Vince Gill, Loretta Lynn, Martina McBride, Brad Paisley, Carrie Underwood, and Keith Urban. Known around the world as "the show that made country music famous," you can count on things happening at the Opry that you just can't see anywhere else. Take in a show or do a backstage tour!

 

Country Music Hall of Fame and Museum

The Country Music Hall of Fame® and Museum is the definitive home of America’s music, safeguarding more than 2.5 million priceless artifacts, including countless recordings and photographs, numerous stage costumes, musical instruments, and more.

 

The Parthenon

The world’s only full-scale reproduction of the famous Greek temple, Nashville's Parthenon stands in Centennial Park and features both the city’s art museum and Athena Parthenos. At almost 42 feet in height, Athena Parthenos is the tallest indoor sculpture in the Western world.

Delete VENUE

Edit Parent - SUPPORT (visibility Show)

EXHIBIT IN NASHVILLE


It is our pleasure to invite you to join us as an exhibitor at our 2018 Clinical Lipid Updates. NLA meetings provide you with an opportunity to reach your target audience of Lipidologists, Cardiologists, Endocrinologists, Primary Care Physicians, PhD researchers, and clinical team affiliates, from an array of disciplines including nurses, nurse practitioners, physician assistants, pharmacists, exercise physiologists, and dietitians, in a uniquely intimate educational setting. We are proud to showcase not only an agenda led by distinguished faculty who are leaders in their fields, but a lively exhibit hall to act as a home-base for our attendees. On behalf of our board of directors and the members we serve, we look forward to seeing you in 2018.

HOST A SYMPOSIUM


The NLA has established that independently developed CME/CE-certified satellite symposia held in conjunction with the scientific meetings of the NLA are valuable opportunities to provide continuing education for our members and meeting participants.

In this regard, we are pleased to offer satellite symposia opportunities in conjunction with our 2018 Spring Clinical Lipid Update. Satellite symposia curriculum should include educational topics that complement or supplement the Spring CLU program agenda, addressing educational gaps preventing optimal patient care. Download our guidelines to view important information regarding hosting a satellite symposium, including the proposal creation and application processes.

Please contact the NLA Program Development department directly should you have any questions or require additional information. We hope to see you in San Antonio!
 

Download Symposia Guidelines


Interested in non-CME programming? Please email exhibits@lipid.org

Delete SUPPORT

Edit Parent - SPECIAL EVENTS (visibility Show)

FOUNDATION EVENT


Put your trivia skills to the test at the Foundation of the NLA’s Fall CLU event!

Join a team of your peers and put your heads together to compete for prizes! Your quizmaster will cover a variety of categories including pop-culture, music, NLA history, and more. Held at the Fall CLU host hotel, enjoy food and drink with a side of friendly competition.

Purchase Your Ticket!
Saturday, September 22
6:30 – 8:30 PM
Lyric Room
$75.00 Per Person

 

Register Now

 

Expert Theaters


Saturday, September 22 | 11:55am - 12:55pm

PRALUENT (Alirocumab) Injection – The Time to Treat is Now

Location: Neely Room


Faculty: Brett Nowlan, M.D.
Cottage Grove Cardiology
West Hartford, CT

Hosted by Sanofi Regeneron


Repatha® (evolocumab): Putting it into Practice

Location: McTyeire Room

Faculty: Eliot A. Brinton, MD, FAHA, FNLA

Hosted by Amgen

SYMPOSIA


 

 
Special Symposium: Severe Hypertriglyceridemia & Pancreatitis: Including Familial Chylomicronemia Syndrome (FCS) in your Differential Diagnosis
Presentation supported by Akcea Therapeutics
 
Friday, September 21
2:15 – 3:15pm
 
SPEAKERS:
Paul D. Rosenblit, MD, PHD, FACE, FNLA
Clinical Professor, Medicine (Div. Endocrinology, Diabetes, Metabolism); 
University of California, Irvine (UCI), School of Medicine
Irvine, CA
 
Seth Baum, MD, FACC, FACPM, FAHA, FNLA, FASPC
President, Preventive Cardiology, Inc
Clinical Affiliate Professor of Medicine at FAU Medical School
Boca Raton, FL
 
Michael Davidson, MD
Clinical Professor of Medicine
Director, Preventive Cardiology
University of Chicago Medicine
Chicago, IL
 
PROGRAM DESCRIPTION:  
Is a patient like this in your practice?
    • Severe, refractory hypertriglyceridemia 
        o TG>880 mg/dL
        o Not responsive to standard triglyceride-lowering therapies
    • No secondary causes of hypertriglyceridemia
    • A history of pancreatitis or recurrent abdominal pain without other explainable cause
 
If so, it could be Familial Chylomicronemia Syndrome (FCS).
 
Objectives for attending clinicians include:
    • Differentiate the FCS patient from patients with secondary causes of hypertriglyceridemia
    • Appreciate the importance of FCS diagnosis
    • Understand the value of connecting FCS patients to educational resources and the FCS patient community
 
Refreshments will be served.

 

 
CME/CE Dinner Symposium - PCSK9 Inhibitors in Practice: Real-World Challenges and Solutions
 
Friday, September 21
7:00 – 9:00pm
 
This activity delves into the treatment advances and clinical considerations in lowering cardiovascular risk through an interactive “Do It Better” activity. Clinical scenarios on the management of hypercholesterolemia will be presented for recognition of suboptimal treatment approaches, followed by faculty discussion. The chance to apply key learnings will then be provided via audience response to multi-faceted management options in a similar clinical scenario. The session will cover important information, such as latest clinical trial data on PCSK9 inhibitors, optimal LCL-C goals, appropriate patients for nonstatin lipid-lowering therapy, common reasons for PCSK9 inhibitor denial, and team-based approaches to improve patient access.
 
SPEAKERS:
Christopher Paul Cannon, MD
Professor of Medicine
Harvard Medical School
Cardiovascular Division
Brigham and Women's Hospital
Boston, MA
 
P.Barton Duell, MD
Professor of Medicine,
Director of Lipid-Atherosclerosis Laboratory
Knight Cardiovascular Institute,
Oregon Health and Science University
Portland, OR
 
MODERATOR: 
Deepak L. Bhatt, MD,MPH
Executive Director of Interventional Cardiovascular Programs
Professor, Harvard Medical School
 
Hosted by Horizon CME.
Delete SPECIAL EVENTS


SCIENTIFIC MEETINGS CO-CHAIRS

Alan S. Brown, MD, FNLA

Committee Co-Chair
President, National Lipid Association
Director, Division of Cardiology

Advocate Lutheran General Hospital
Co-Director, Cardiology Service Line
Advocate Medical Group
Clinical Associate Professor
Loyola Stritch School of Medicine
Park Ridge, IL

Anne C. Goldberg, MD, FACP, FNLA

Committee Co-Chair
President, Foundation of the NLA

Professor of Medicine
Washington University School of Medicine
St. Louis, MO



PROGRAM PLANNERS

Sergio Fazio, MD, PhD, FNLA

Program Planner
William and Sonja Connor Chair of Preventive Cardiology
Professor of Medicine
Director of Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health and Science University
Portland, OR

Edward A. Gill, MD, FNLA

Program Planner
Director of Interventional Echocardiography
Professor of Medicine
Division of Cardiology
University of Colorado School of Medicine, Anschutz
Aurora, CO

Antonio M. Gotto, MD, DPhil, FNLA

Program Planner
President-Elect, National Lipid Association

Dean Emeritus
Weill Cornell Medicine
New York, NY

Elizabeth Jackson, MSN, ACNS-BC, CLS, FNLA

Program Planner
Cardio Texas
St. David's Medical Center
Austin, TX

Peter H. Jones, MD, FNLA

Program Planner
Director, Division of Cardiology
Associate Professor of Medicine Co-director, 
Lipid Metabolism and Atherosclerosis Clinic Center for
Cardiovascular Disease Prevention
Houston Methodist DeBakey Heart and Vascular Center 
Baylor College of Medicine 
Houston, TX

Carol Kirkpatrick, PhD, RDN, MPH, CLS, FNLA

Program Planner
Wellness Center Director
Clinical Assistant Professor
Idaho State University
Pocatello, ID

 

Pamela B. Morris, MD, FNLA

Program Planner
President, Southeast Lipid Association

Director, Preventive Cardiology
Co-Director, Women’s Heart Care
Medical University of South Carolina
Charleston, SC

Joseph J. Saseen, PharmD, CLS, FNLA

Program Planner
Secretary/Treasurer, National Lipid Association

Professor and Vice Chair
Department of Clinical Pharmacy
Professor, Department of Family Medicine
University of Colorado
Anschutz Medical Campus
Aurora, CO

Daniel E. Soffer, MD, FNLA

Program Planner
President, Northeast Lipid Association

University of Pennsylvania Health System
Internal Medicine/Clinical Lipidology
Perelman Center for Advanced Medicine
Philadelphia, PA



FACULTY

Lori A. Alexander, MSHS, RD, CLS, FNLA

Director, Lipid Center of Excellence
Jacksonville Center for Clinical Research
Jacksonville, FL

Karen E. Aspry, MD, MS, FNLA

Director, Lipid Clinic and Cardiovascular
  Disease Prevention Program
Lifespan Cardiovascular Institute
East Greenwich, RI

Jan N. Basile, MD

Professor of Medicine
Medical University of South Carolina
Charleston, SC

Michael J. Blaha, MD, MPH

Director of Clinical Research
Johns Hopkins Ciccarone Center for the Prevention of Heart Disease
Baltimore, MD

Marc P. Bonaca, MD, MPH

Assistant Professor
Harvard Medical School
Boston, MA

Kathleen H. Byrne, CRNP

Clinical Manager/ Study Coordinator
Johns Hopkins University Lipid Clinic
Baltimore, MD

Christopher P. Cannon, MD

Director, Education, Cardiovascular Medicine Innovation
Cardiovascular Division
Brigham and Women’s Hospital
Professor of Medicine
Harvard Medical School
Boston, MA

Karen Collins, MS, RDN, CDN, FAND

Speaker, Writer, Consultant
Nutrition Advisor, American Institute for Cancer Research
Past Chair, SCAN dietetic practice group
Jamestown, NY

Keith C. Ferdinand, MD, FNLA

Professor of Medicine
School of Medicine
Tulane University
New Orleans, LA

Edward A. Fisher, MD, PhD, FNLA

Leon H. Charney Professor of Cardiovascular Medicine
Department of Medicine
New York University
New York, NY

Debra A. Friedrich, DNP, FNP-BC, CLS, FNLA

Assistant Professor, Adult Gerontology
Concentration Director
DNP Project/Practicum Coordinator
University of South Florida, College of Nursing
Tampa, FL

Edward A. Gill, MD, FNLA

Program Planner
Director of Interventional Echocardiography
Professor of Medicine
Division of Cardiology
University of Colorado School of Medicine, Anschutz
Aurora, CO

Anne C. Goldberg, MD, FACP, FNLA

Committee Co-Chair
President, Foundation of the NLA

Professor of Medicine
Washington University School of Medicine
St. Louis, MO

John R. Guyton, MD, FNLA

Professor of Medicine
Assistant Professor of Pathology
Department of Medicine
Duke University School of Medicine
Durham, NC

Linda C. Hemphill, MD, FNLA

Instructor in Medicine
Harvard Medical School
Director
LDL Apheresis Unit
Massachusetts General Hospital
Boston, MA

Dean G. Karalis, MD, FNLA

Cardiology Consultants of Philadelphia
Philadelphia, PA

Alice H. Lichtenstein, DSc, MS

Gershoff Professor Nutrition and Policy
Tufts University
Boston, MA

Seth S. Martin, MD, MHS

Assistant Professor of Medicine
Division of Cardiology
Department of Medicine
Johns Hopkins University School of Medicine
Director, Advanced Lipid Disorders Program Ciccarone Center for
 the Prevention of Cardiovascular Disease
Baltimore, MD

Jan L. McAlister, DNP, CLS, FNLA

Nurse Practitioner
Piedmont Healthcare
Atlanta, GA

Kellie H. McLain, ANP-BC, CLS

Medical University of South Carolina
Division of Cardiology
Charleston, SC

Joseph J. Saseen, PharmD, CLS, FNLA

Program Planner
Secretary/Treasurer, National Lipid Association

Professor and Vice Chair
Department of Clinical Pharmacy
Professor, Department of Family Medicine
University of Colorado
Anschutz Medical Campus
Aurora, CO

Vikesh K. Singh, MD, MSc

Associate Professor of Medicine
Director, Pancreatitis Center
Medical Director, Pancreatic Islet Autotransplantation Program
Division of Gastroenterology
Johns Hopkins University School of Medicine
Baltimore, MD

Daniel E. Soffer, MD, FNLA

Program Planner
President, Northeast Lipid Association

University of Pennsylvania Health System
Internal Medicine/Clinical Lipidology
Perelman Center for Advanced Medicine
Philadelphia, PA

John M. Stafford, MD, PhD

Associate Professor
Department of Medicine
Division of Diabetes, Endocrinology, & Metabolism
and Molecular Physiology and Biophysics
Vanderbilt University Medical Center
Nashville, TN

James A. Underberg, MD, MS, FNLA

Committee Co-Chair
President, National Lipid Association

Clinical Assistant Professor of Medicine
Director, Bellevue Hospital Lipid Clinic
New York, NY

Anish K. Vani, MD

Cardiovascular Disease, Prevention Fellow
Leon H. Charney Division of Cardiology
NYU School of Medicine
New York, NY

Barbara S. Wiggins, PharmD, CLS, FNLA

Pharmacy Clinical Specialist- Cardiology
Medical University of South Carolina
Charleston, SC



Register for 2018 Fall Clinical Lipid Update

Registration Options

Login for the member rate

Members

Non-Members

Trainees

Main Session

September 21-23, 2018

Masters in Lipidology Live Course

September 20-21, 2018

Foundations of Lipidology Live Course

September 20-21, 2018

$ 0.00
Paper application only

Team Trivia Night
Foundation Event

September 22nd, 2018

Guest Ticket


Join the NLA and save on registration


NLA Membership


Interested in the Trainee Rate?


Enrolled in a graduate or postgraduate training program and want to attend at the Trainee Member rate?

Apply now for free



Disclaimer


Lipid Bucks: Lipid Bucks can be applied on the checkout page.

Registration: Online registration and payment must be received no later than September 20, 2018. After this date, meeting materials and name badge cannot be guaranteed, but onsite registration will be available until September 23, 2018. By registering for this meeting, attendee understands and agrees that attendee’s name, city, and state may be shared with other attendees and exhibitors. By allowing an exhibitor to scan the conference badge, attendee understands, agrees and consents to the sharing of attendee’s contact information with the company that scanned the conference badge.

Cancellation: Telephone cancellations will not be accepted. A written notice of cancellation must be received no later than August 21, 2018. This includes social events and guest fees. There will be a $100 fee for all cancellations. There will be no refunds if cancelling within 30 days of the start of the meeting date.

Attendees who need special reasonable accommodations or who have special needs should contact the meeting organizers at 904-998-0854.